You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hocanalyses of the EPOC trial
BMC Neurology, November 2014
Jonathan Calkwood, Bruce Cree, Heidi Crayton, Daniel Kantor, Brian Steingo, Luigi Barbato, Ron Hashmonay, Neetu Agashivala, Kevin McCague, Nadia Tenenbaum, Keith Edwards
The data shown below were compiled from readership statistics for 60 Mendeley readers of this research output. Click here to see the associated Mendeley record.
|Readers by professional status||Count||As %|
|Student > Master||8||13%|
|Student > Bachelor||6||10%|
|Student > Ph. D. Student||6||10%|
|Readers by discipline||Count||As %|
|Medicine and Dentistry||21||35%|
|Nursing and Health Professions||5||8%|
|Pharmacology, Toxicology and Pharmaceutical Science||4||7%|